Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
NCT00113646Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2002
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siplizumab in lymphoma, leukemia, multiple myeloma (MM), myelodysplastic syndrome (MDS), sponsored by Massachusetts General Hospital. Started Nov 2002; status: terminated.
02
Drugs
siplizumab
03
Conditions
lymphomaleukemiamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00113646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113646.